OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HAO$0.7156

Haoxi Health Technology Ltd

Advertising & MarketingVerified

Haoxi Health Technology Ltd maintains a strong liquidity position, with cash and equivalents amounting to $6.66 million, representing 42.9% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 0.295, indicating a solid ability to meet short-term obligations. The current ratio of 3.98 further supports this, showing that the company has nearly four times as many current assets as current liabilities. However, the operating cash flow is negative at -$747,580, which may signal short-term operational inefficiencies or investment in growth. Profitability metrics show a return on equity (ROE) of 11.46% and a return on assets (ROA) of 8.33%, both of which are strong indicators of efficient capital use and asset management. The company's net income of $1.29 million and operating income of $1.72 million suggest a healthy margin structure. However, the gross profit margin of 5.66% is relatively low compared to industry benchmarks, indicating potential pricing or cost pressures. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment-specific revenue data limits the ability to assess the performance of different business lines or geographic regions. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The current fiscal year's revenue of $48.52 million is expected to remain relatively flat, with a marginal change in the next fiscal year. The company's capital expenditure of -$55,370 suggests a reduction in investment in physical assets, which may indicate a shift toward digital or service-based growth strategies. The risk assessment indicates a low probability of dilution and no immediate liquidity concerns. The debt-to-equity ratio of 0.10 suggests a conservative capital structure with minimal reliance on debt financing. However, the negative operating cash flow and the absence of detailed risk disclosures in recent filings warrant closer monitoring of operational efficiency and potential liquidity pressures. Recent filings and transcripts do not highlight any major events or strategic shifts. The company has not disclosed any significant new contracts, regulatory changes, or strategic partnerships that would materially impact its operations or financial performance. The lack of recent events suggests a stable but potentially stagnant business environment for Haoxi Health Technology Ltd.

30-day price · HAO-0.38 (-34.2%)
Low$0.45High$1.19Close$0.73As of10 May, 00:00 UTC
Profile
CompanyHaoxi Health Technology Ltd
TickerHAO.O
SectorConsumer Cyclicals
BusinessCyclical Consumer Services
Industry groupCyclical Consumer Services
IndustryAdvertising & Marketing
AI analysis

Business. Haoxi Health Technology Ltd provides advertising and marketing services, generating revenue primarily through service fees and client contracts.

Classification. Haoxi Health Technology Ltd is classified under the Advertising & Marketing industry within the Cyclical Consumer Services business sector, with a classification confidence of 0.92.

Haoxi Health Technology Ltd maintains a strong liquidity position, with cash and equivalents amounting to $6.66 million, representing 42.9% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 0.295, indicating a solid ability to meet short-term obligations. The current ratio of 3.98 further supports this, showing that the company has nearly four times as many current assets as current liabilities. However, the operating cash flow is negative at -$747,580, which may signal short-term operational inefficiencies or investment in growth. Profitability metrics show a return on equity (ROE) of 11.46% and a return on assets (ROA) of 8.33%, both of which are strong indicators of efficient capital use and asset management. The company's net income of $1.29 million and operating income of $1.72 million suggest a healthy margin structure. However, the gross profit margin of 5.66% is relatively low compared to industry benchmarks, indicating potential pricing or cost pressures. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment-specific revenue data limits the ability to assess the performance of different business lines or geographic regions. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The current fiscal year's revenue of $48.52 million is expected to remain relatively flat, with a marginal change in the next fiscal year. The company's capital expenditure of -$55,370 suggests a reduction in investment in physical assets, which may indicate a shift toward digital or service-based growth strategies. The risk assessment indicates a low probability of dilution and no immediate liquidity concerns. The debt-to-equity ratio of 0.10 suggests a conservative capital structure with minimal reliance on debt financing. However, the negative operating cash flow and the absence of detailed risk disclosures in recent filings warrant closer monitoring of operational efficiency and potential liquidity pressures. Recent filings and transcripts do not highlight any major events or strategic shifts. The company has not disclosed any significant new contracts, regulatory changes, or strategic partnerships that would materially impact its operations or financial performance. The lack of recent events suggests a stable but potentially stagnant business environment for Haoxi Health Technology Ltd.
Key takeaways
  • Haoxi Health Technology Ltd has a strong liquidity position with a current ratio of 3.98 and cash and equivalents of $6.66 million.
  • The company's profitability is robust, with an ROE of 11.46% and ROA of 8.33%, but its gross profit margin is relatively low at 5.66%.
  • Revenue is concentrated in a single business segment, with no geographic diversification disclosed, increasing exposure to regional risks.
  • The company is expected to maintain a stable revenue trajectory with no significant growth or decline projected in the next fiscal year.
  • The risk assessment indicates a low probability of dilution and no immediate liquidity concerns, with a conservative debt-to-equity ratio of 0.10.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$48.5M
Gross profit$2.8M
Operating income$1.7M
Net income$1.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$747.6k
CapEx-$55.4k
Free cash flow$1.2M
Total assets$15.5M
Total liabilities$4.2M
Total equity$11.3M
Cash & equivalents$6.7M
Long-term debt$1.1M
Valuation
Market price$0.71
Market cap$41.9M
Enterprise value$36.4M
P/E32.5
Reported non-GAAP P/E
EV/Revenue0.8
EV/Op income21.2
EV/OCF
P/B3.7
P/Tangible book3.7
Tangible book$11.3M
Net cash$5.5M
Current ratio4.0
Debt/Equity0.1
ROA8.3%
ROE11.5%
Cash conversion-58.0%
CapEx/Revenue-0.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Advertising & Marketing · cohort 239 companies
MetricHAOActivity
Op margin3.5%3.6% medp25 -1.9% · p75 9.8%below median
Net margin2.7%2.3% medp25 -2.8% · p75 7.5%above median
Gross margin5.7%33.3% medp25 17.9% · p75 54.3%bottom quartile
CapEx / revenue-0.1%-1.2% medp25 -4.0% · p75 -0.4%top quartile
Debt / equity10.0%22.8% medp25 2.9% · p75 58.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 18:45 UTC#8e76cf1f
Market quoteclose USD 0.65 · shares 0.06B diluted
no public URL
2026-05-10 05:29 UTC#0efd7ede
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 02:30 UTCJob: 3c9c6150